Ocular and Adnexal Lymphoma (eng)

This book is a comprehensive source of authoritative information on the subject of ocular and adnexal lymphoma. It is a completely updated edition of its predecessor and is a conjoint effort of ocular oncologists, general oncologists, and pathologists. The book features contributions from around the world to ensure broad coverage of an evolving topic. 
Chapters cover all aspects of ocular lymphomas, including clinical features, classification, epidemiology, diagnostic evaluation, biopsy techniques, histology and molecular pathology, staging procedures, and treatment methods. The emphasis throughout is on easy readability, and the layout ensures rapid retrieval of information. The book offers a clear distinction of what has been updated in the years since the first edition published, including entirely rewritten or revamped chapters. In order to convey fundamental concepts, numerous tables, clinical photographs, histopathologic microphotographs, and imaging studies (fluorescein and indocyanine angiograms, ultrasonograms, CT scans, and MR images) are included.
Ocular and Adnexal Lymphoma strives to cover new developments and innovations in ocular and adnexal lymphoma, providing the clinician with a review and summary of recent research and its implications for clinical practice and explaining how research results impact diagnostics, treatment options and procedures as well as patient management.

​Arun D. Singh, MD, is Director of the Department of Ophthalmic Oncology at the Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio. Dr. Singh studied at the University of Madras and the All India Institute of Medical Sciences, New Delhi, before gaining his FRCS (Royal College of Surgeons, Edinburgh) and FRCOphth (Royal College of Ophthalmologists) in the United Kingdom. He trained and worked at Wills Eye Hospital in Philadelphia before taking up his present position in 2003. In 2009 Dr. Singh received a Senior Achievement Award from the American Academy of Ophthalmology. Since 2009 he has also been Professor of Ophthalmology at the Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio. Dr. Singh is co-Editor-in-Chief of the British Journal of Ophthalmology. He has authored more than 100 book chapters and more than 250 journal articles and has edited 10 books. He has been an invited speaker at several universities, including Harvard University, Yale University, Cambridge University, and Emory University.

Vishal R Raval, MD completed his primary medical education from Nashik District Maratha Vidya Prasarak Samaj's Medical College, Nasik and his DNB in Ophthalmology from K J Somaiya Medical College, Mumbai. He did a Research cum Vitreo-retinal fellowship from Sankara Nethralaya, Chennai, before joining LVPEI in 2013.
He later did his International Ophthalmic Research Fellowship in Ocular Oncology at Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA, under Dr Arun Singh, as his mentor.
He has published widely in the peer-reviewed journals and presented at various conferences. His areas of clinical interest are in the field of vitreoretinal diseases such as diabetic retinopathy, retinal detachment, and ocular oncology including management of intraocular tumors such as retinoblastoma, choroidal melanoma & various other retinal & choroidal tumors. In the research front, he is keen on translational animal research in the field of ocular oncology, particularly retinoblastoma.
Prithvi Mruthyunjaya, MD, MHS  is Associate Professor of Ophthalmology at Stanford Univeristy, member of the Vitreoretinal Surgery Service and is the new Director of Ocular Oncology at the Byers Eye Institute. He is a board certified ophthalmologist who has completed two prestigious fellowships: the first in Vitreoretinal Surgery at Duke University and the second in Ocular Oncology at Moorfields Eye Hospital in London, England. He cares for patients with conditions related to cancer of the eye in both adults and children--either benign, pre-cancerous, or eye cancer. These conditions include ocular melanoma, hemangioma, cancers from other parts of the body which spread to the eye, Coats' disease, retinoblastoma, iris tumors (melanoma, cysts, metastatic lesions) and tumors of the conjunctiva including melanoma, and squamous cells carcinoma. He also manages the eye related side effects of chemotherapy treatments. He is an expert in using the most advanced diagnostic tests to make a personalized treatment plan for every patient. With his expertise in retinal surgery, he treats patients with a variety of advanced techniques including small instrument tumor biopsy, vitrectomy, and radiation therapy. As a retinal surgeon, he manages complicated retinal diseases including retinal detachment, macular holes, epiretinal membranes, and diabetic eye disease.
Dr. Mruthyunjaya is actively involved in research in ocular cancer imaging, genetics, and new modalities of tumor biopsy. His passion lies in developing collaborative research networks and training the next generation of vitreoretinal surgeons. His academic contributions were recognized by the Heed, AOS-Knapp and Ronald G Michels foundations the American Society of Retina Specialists with a Senior Honor Award. He was recently listed as one of the worlds 150 most innovative retinal specialists.